Cocaine-evoked negative symptoms require AMPA receptor trafficking in the lateral habenula

Nature Neuroscience

Volumn 18, Issue 3, 2015, Pages 376-380

  Meye, Frank J ^a,b   Valentinova, Kristina ^a,b   Lecca, Salvatore ^a,b   Marion Poll, Lucile ^a,b   Maroteaux, Matthieu J ^a,b   Musardo, Stefano ^c   Moutkine, Imane ^a,b   Gardoni, Fabrizio ^c   Huganir, Richard L ^d   Georges, François ^e,f   Mameli, Manuel ^a,b  

^a INSTITUT DU FER À MOULIN   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c UNIVERSITY OF MILAN   (Italy)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e CNRS   (France)

^f UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPA RECEPTOR; COCAINE; DOPAMINE UPTAKE INHIBITOR; GLUTAMATE RECEPTOR IONOTROPIC, AMPA 1; GREEN FLUORESCENT PROTEIN; PHOTOPROTEIN; RED FLUORESCENT PROTEIN;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AVERSIVE BEHAVIOR; BRAIN NERVE CELL; COCAINE DEPENDENCE; CONTROLLED STUDY; EVOKED RESPONSE; EXCITATORY POSTSYNAPTIC POTENTIAL; HABENULA; MOUSE; NEGATIVE SYNDROME; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VENTRAL TEGMENTUM; ANIMAL; C57BL MOUSE; CYTOLOGY; DRUG EFFECTS; ELECTROSTIMULATION; GENETICS; IMMOBILIZATION; IN VITRO STUDY; INSTRUMENTAL CONDITIONING; METABOLISM; MOTOR ACTIVITY; MUTATION; PATCH CLAMP TECHNIQUE; PHYSIOLOGY; PROTEIN TRANSPORT; PSYCHOLOGY; SWIMMING; TRANSGENIC MOUSE;

ANIMALS; COCAINE; CONDITIONING, OPERANT; DOPAMINE UPTAKE INHIBITORS; ELECTRIC STIMULATION; EXCITATORY POSTSYNAPTIC POTENTIALS; GREEN FLUORESCENT PROTEINS; HABENULA; HINDLIMB SUSPENSION; IN VITRO TECHNIQUES; LUMINESCENT PROTEINS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOTOR ACTIVITY; MUTATION; PATCH-CLAMP TECHNIQUES; PROTEIN TRANSPORT; RECEPTORS, AMPA; SWIMMING;

EID: 84923782492     PISSN: 10976256     EISSN: 15461726     Source Type: Journal    
DOI: 10.1038/nn.3923     Document Type: Article

References (23)

1. Koob, G.F. & Le Moal, M. Phil. Trans. R. Soc. Lond. B 363, 3113-3123 (2008).
2. Barr, A.M., Markou, A. & Phillips, A.G. Trends Pharmacol. Sci. 23, 475-482 (2002).
3. Stamatakis, A.M. & Stuber, G.D. Nat. Neurosci. 15, 1105-1107 (2012).
4. Jhou, T.C., Fields, H.L., Baxter, M.G., Saper, C.B. & Holland, P.C. Neuron 61, 786-800 (2009).
5. Li, B. et al. Nature 470, 535-539 (2011).
6. Maroteaux, M. & Mameli, M. J. Neurosci. 32, 12641-12646 (2012).
7. Zuo, W., Chen, L., Wang, L. & Ye, J.H. Neuropharmacology 70, 180-189 (2013).
8. Meye, F.J., Lecca, S., Valentinova, K. & Mameli, M. Front. Hum. Neurosci. 7, 860 (2013).
9. Rumpel, S., LeDoux, J., Zador, A. & Malinow, R. Science 308, 83-88 (2005).
10. Liu, B., Wang, S., Brenner, M., Paton, J.F. & Kasparov, S. J. Gene Med. 10, 583-592 (2008).
11. Malinow, R. Phil. Trans. R. Soc. Lond. B 358, 707-714 (2003).
12. Friedman, A.K. et al. Science 344, 313-319 (2014).
13. Li, K. et al. Science 341, 1016-1020 (2013).
14. Porsolt, R.D., Bertin, A. & Jalfre, M. Arch. Int. Pharmacodyn. Ther. 229, 327-336 (1977).
15. Matsumoto, M. & Hikosaka, O. Nature 447, 1111-1115 (2007).
16. Jhou, T.C. et al. J. Neurosci. 33, 7501-7512 (2013).
17. Weiss, F., Markou, A., Lorang, M.T. & Koob, G.F. Brain Res. 593, 314-318 (1992).
18. Maroteaux, M. & Mameli, M. J. Neurosci. 32, 12641-12646 (2012).
19. Rumpel, S., LeDoux, J., Zador, A. & Malinow, R. Science 308, 83-88 (2005).
20. Glangetas, C. et al. J. Neurosci. 33, 19657-19663 (2013).
21. Kowski, A.B., Veh, R.W. & Weiss, T. Neuroscience 161, 1154-1165 (2009).
22. Valjent, E. et al. Neuropsychopharmacology 35, 401-415 (2010).
23. Porsolt, R.D., Bertin, A. & Jalfre, M. Arch. Int. Pharmacodyn. Ther. 229, 327-336 (1977).